MIG-HD: Multicentric Intracerebral Grafting in Huntington's Disease

Huntington Disease Clinical Trial

— MIG-HD  

Official title:

Multicentric Intracerebral Grafting in Huntington's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00190450
• Other study ID #: P 001106
• Status: Completed
• Phase: Phase 2
• First received: September 15, 2005
• Last updated: October 12, 2017
• Start date: January 2002
• Est. completion date: December 2013

Study information

• Verified date: October 2017
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to assess the clinical benefit of intrastriatal grafting of human cells from the foetal ganglionic eminence in patients with Huntington's disease. The duration of the study will be 52 months. A first group of patients will be grafted at M13-14 (early G group) and a second group of patients will be grafted at M33-34 (late G group). The principal criterion is the comparison of the progression between M12 and M32 of the motor score (TMS) of the UHDRS between grafted patients (early G group) and not yet grafted patients (late G group). An additional evaluation will be performed to compare the progression in individual patients over the 52-month study period. We will thus be able to compare the pre and post-graft TMS progression for all patients.

Description:

The aim of this study is to show the existence of a clinical benefit rising from a substitution of the striatal neurons degenerated among a large cohort of Huntington's patient at early stage by homologous neurons coming from human foetuses, This effect will be estimated, compared with a group of patients not treated at first, on the results of the motor scale of the Unified Huntington Disease Rating Scale (UHDRS, Huntington study group, on 1996).

Transplants will be realized in two surgical times to avoid the risk of hurts per-operating, BI-CAUDES, if transplants were realized at single time. The minimal interval between both transplants will be of 2 weeks, so as to let the patient recover of the first general anaesthesia It's a multicentric study of phase II randomised and controlled, with direct individual benefit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Disease clinically declared since at least 1 year ,UHDRS motor > or =5

• TFC > or = 10.

• CAG > or = 36

• Age between 18 and 65

• Family and socially integrated subject

• Informed consent.

Exclusion Criteria:

• Severe intellectual deterioration or neuropsychiatric disorders making the follow-up longitudinal too complicated (score MATTIS < 120).

• Not-observance of the appointments and the symptomatic treatments in pre-surgical period.

• Intercurrent disease making a surgical operation impossible.

• Associated disease having a neurological repercussion, intercurrent cerebral lesion with the IRM.

• Visceral affection engraves, evolutionary, which brings into play the vital forecast or makes risks for general anaesthesia.

• Mental Affection likely to disturb adhesion with the protocol, and in particular antecedents of hallucinations spontaneous and/or induced by the drugs; antecedents of serious depression having required repeated hospitalizations; antecedents of repeated suicide attempts.

• Cerebral morphological anomalies, others that those characteristic of the disease, noted with the IRM or the tomodensitometry.

• Participation in progress, or stopped since less than three months, with a therapeutic protocol of the Huntington's disease Exclusion Criteria (pre-randomization)

• TFC < 8

• Not-observance of the appointments and the symptomatic treatments in pre-surgical period.

• Intercurrent disease returning the surgery or impossible immunosuppression. v Subject completely isolated with his family and socially..

• UHDRS motor < 5.

• Positives serologies for HIV1, HIV2, AgP24, HTLV1 et 2, HEPATITE B, HEPATITE C, syphilis

• Psychiatric disorders being able to compromise the follow-up.

• Signs other than Huntington with the IRM.

Related Conditions & MeSH terms

• Huntington Disease

Intervention

Biological:
• graft intracerebral of foetal neurons
graft intracerebral of foetal neurons

Locations

Country	Name	City	State
France	Hopital Henri Mondor	Paris	Ile de France

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

References & Publications (1)

Bachoud-Lévi AC, Rémy P, Nguyen JP, Brugières P, Lefaucheur JP, Bourdet C, Baudic S, Gaura V, Maison P, Haddad B, Boissé MF, Grandmougin T, Jény R, Bartolomeo P, Dalla Barba G, Degos JD, Lisovoski F, Ergis AM, Pailhous E, Cesaro P, Hantraye P, Peschanski — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Motor UHDRS rating scale, at randomization, 20 month after transplant		during de study
Secondary	Neurologic, Cognitive, Neurophysiologic, Psychiatric, MRI and Pet-scan evaluation at randomization, 20 month after and at the end of the protocol		during the study

External Links

•   Huntington french speaking network website